STEEPLE bleeding criteria: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
m (Bot: Removing from Primary care) |
||
Line 26: | Line 26: | ||
== References == | == References == | ||
{{Reflist}} | {{Reflist}} | ||
{{WH}} | |||
{{WS}} | |||
[[Category:Medical emergencies]] | [[Category:Medical emergencies]] | ||
[[Category:Blood]] | [[Category:Blood]] | ||
[[Category:Hematology]] | [[Category:Hematology]] | ||
Latest revision as of 00:17, 30 July 2020
Bleeding Microchapters |
Treatment |
---|
Reversal of Anticoagulation and Antiplatelet in Active Bleed |
Perioperative Bleeding |
STEEPLE bleeding criteria On the Web |
American Roentgen Ray Society Images of STEEPLE bleeding criteria |
Risk calculators and risk factors for STEEPLE bleeding criteria |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Steeple Bleeding Criteria (DO NOT EDIT)[1]
“ |
Safety and Efficacy Of Enoxaparin In Percutaneous Coronary Intervention Patients: An International Randomized Evaluation Major Bleeding
Minor
|
” |
References
- ↑ Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J; et al. (2009). "Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial". Circulation. 119 (5): 680–6. doi:10.1161/CIRCULATIONAHA.108.803528. PMID 19171853.